Faruqi and Faruqui, LLP Logo
Share this page

Cases: Antitrust Litigation

1 2 3 >
Page 1 of 3 (46 Items)
12
Nov
2015

In re Lamictal Direct Purchaser Antitrust Litig., No. 12-00995 (D.N.J.)

In the Lamictal case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of SmithKline Beacham’s Lamictal, prescription drugs used to treat epilepsy, bipolar disorder and other medical conditions.  The class also includes direct purchasers of generic versions of Lamictal from Teva, SmithKline’s co-defendant and... READ MORE

14
Oct
2015

Smith Drug Co. v. Actavis (Namenda), No. 15-7488 (S.D.N.Y.)

In the Namenda case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Actavis’ memantine hydrochloride, sold under the brand name Namenda and Namenda XR.  The complaint alleges that Actavis engaged in an illegal product hop to move the market from Namenda to Namenda... READ MORE

13
Sep
2014

In re Celebrex Antitrust Litig., No. 14-00361 (E.D. Va.)

In the Celebrex case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Pfizer’s blockbuster anti-inflammatory drug, Celebrex.  The case alleges that Pfizer procured a patent by committing Walker Process fraud and then filed patent litigation against generic drugmakers Teva Watson and Mylan, to... READ MORE

04
Jun
2014

In re Opana Antitrust Litig., No. 14-10150 (N.D. Ill.)

In the Opana case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Endo Pharmaceuticals’ Oxymorphone ER, sold under the brand name Opana ER.  The proposed class alleges that Endo and would-be generic competitor Impax Laboratories entered an illegal reverse payment agreement under which... READ MORE

11
Dec
2013

In re Lidoderm Antitrust Litig., No. 14-2521 (N.D. Cal.)

In the Lidoderm case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Endo’s 5% lidocaine patch, Lidoderm.  The case alleges that Endo paid its would-be generic competitor, Watson (now known as Actavis) hundreds of millions of dollars to delay entering the market with... READ MORE

02
Dec
2013

In re Aggrenox Antitrust Litig., No. 14-2516 (D. Conn.)

In the Aggrenox case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Boehringer Ingelheim’s combination stroke prevention drug, Aggrenox.  The case alleges that Boehringer paid its would-be generic competitors (Duramed, later known as Barr, and still later known as Teva) to delay launching... READ MORE

23
Jul
2013

In re Solodyn Antitrust Litig., No. 14-10438 (D. Mass.)

In the Solodyn case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Medicis’s minocycline drug, Solodyn.  The case alleges that Medicis engaged in an anticompetitive scheme to prevent lower-priced generic competition from entering the market.  The scheme included product reformulations to prevent pharmacists... READ MORE

19
Jun
2013

In re Loestrin 24 Fe Antitrust Litig., No. 13-2472 (D.R.I.)

In the Loestrin case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Warner Chilcott’s oral contraceptive drug, Loestrin 24 Fe.  The class alleges that Warner Chilcott and would-be generic competitors entered into a “pay for delay” conspiracy, to prevent purchasers from benefitting from... READ MORE

05
Apr
2013

In re Niaspan Antitrust Litig., No. 13-cv-1820 (E.D. Pa.)

In the Niaspan case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Abbott Laboratories’ triglyceride drug, Niaspan, whose active ingredient is niacin (vitamin B6).  Faruqi & Faruqi filed the first direct purchaser complaint in this case.  The case alleges that the successive brand... READ MORE

05
Mar
2013

In re Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litig., No. 13-cv-2445 (E.D. Pa.)

In the Suboxone case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Reckitt Benckiser’s opioid addiction drug, Suboxone.  The proposed class alleges that Reckitt took several actions to suppress competition from generic versions of Suboxone, including reformulating Suboxone into a film (for which... READ MORE

27
Aug
2012

In re Nexium (Esomeprazole) Antitrust Litigation, No. 1:12-md-02409-WGY (D. Mass.)

In Nexium, Faruqi & Faruqi, who filed the very first complaint on behalf of direct purchasers, represents a certified class of direct purchasers of the prescription drug Nexium.  The direct purchaser class alleges that in the brand manufacturer, AstraZeneca, entered into illegal reverse-payment agreements with certain generic manufacturers (namely Ranbaxy,... READ MORE

18
Jul
2012

Mylan Pharmaceuticals, Inc. v. Warner Chilcott Public Limited Company, et al. No. 12-3824 (E. D. Pa.)

In this case, nicknamed the Doryx case, Faruqi & Faruqi, LLP represents a pharmaceutical wholesaler and a class of direct purchasers of Warner-Chilcott’s branded drug, Doryx (delayed-release doxycycline hyclate).  The case alleges that Warner-Chilcott and its licensor, Mayne Pharmaceuticals, to forestall competition from less-expensive generic versions of Doryx, hatched an... READ MORE

23
Jan
2012

In re Skelaxin (Metaxalone) Antitrust Litigation, No. 12-MD-2343 (E.D. Tenn.)

In this case, nicknamed Skelaxin, Faruqi & Faruqi, LLP represented a pharmaceutical wholesaler and a class of direct purchasers of the muscle relaxant drug Skelaxin (metaxalone), which has been on the market, without generic competition, since the 1960s. The suit alleged that the brand manufacturer (King) and a generic drug... READ MORE

16
Dec
2011

In re Lipitor Antitrust Litigation, No. 12-2389 (PGS/DEA) (D.N.J.)

In this case, nicknamed Lipitor, Faruqi & Faruqi, LLP represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Pfizer’s branded blockbuster cholesterol drug Lipitor (atorvastatin calcium), and direct purchasers of generic Lipitor manufactured by Ranbaxy.  The case alleges that Pfizer and its predecessors and affiliates engaged in... READ MORE

14
Dec
2011

In re Effexor XR Antitrust Litigation, No. 11-cv-5479 (D.N.J.)

In the Effexor XR case, Faruqi & Faruqi, LLP represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Wyeth’s (now Pfizer’s) branded antidepressant drug Effexor XR (extended-release venlafaxine hydrochloride capsules).  The class also includes direct purchasers of generic versions of Effexor XR from Teva, Wyeth’s co-defendant and... READ MORE

09
Dec
2011

Castro et al. v. Sanofi Pasteur, Inc., No. 11-cv-07178 (D. N. J.)

Faruqi & Faruqi represents a proposed class of pediatricians and pediatric practice groups challenging Sanofi-Pasteur, Inc.’s illegal maintenance of a monopoly on the children’s vaccine Menactra in violation of  § 2 of the Sherman Act.  Plaintiffs allege a scheme where Sanofi-Pasteur employs a series of anticompetitive and exclusionary bundling and... READ MORE

02
Nov
2011

Brownson v. Furukawa Electric Co., Ltd. et al, No. 11-14831(E.D. Mich.)

Faruqi & Faruqi represents a proposed class of users of wire harnesses in automobiles against parts manufacturers who pleaded guilty to Department of Justice charges of an conspiracy to fix prices, violating § 1 of the Sherman Act.  Defendants are manufacturers of automotive wiring harnesses.  Defendants drew the attention of... READ MORE

16
Aug
2011

Sotomayor v. Hachette Book Group Inc., et al., No. 11-05707 (S.D.N.Y.)

Faruqi & Faruqi represents a proposed class of e-book purchasers alleging a horizontal conspiracy among book publishers and e-book sellers in the United States to raise, fix, stabilize and maintain retail prices of e-books.

26
Jan
2011

Broadway v. JP Morgan Chase & Co. et al., No. 11-cv-00398 (E.D.N.Y.)

Faruqi & Faruqi represents a proposed class of silver traders that transacted in COMEX silver futures and option contracts.  This lawsuit, against affiliates of JP Morgan and others, challenges defendants’ alleged conspiracy to manipulate prices of COMEX silver futures and options in violation of § 1 of the Sherman Act... READ MORE

30
Jun
2010

In re Iowa Ready-Mixed Concrete Antitrust Litigation, No. C 10-4038 (N.D. Ia.)

Faruqi & Faruqi represented a class of direct purchasers alleging producers and sellers of ready-mixed concrete conspired to fix prices in violation of § 1 of the Sherman Act.  This case settled for $18.5 million in 2011.

1 2 3 >
Page 1 of 3 (46 Items)